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2Abstract
The ability of cells to respond to changes in oxygen availability is critical for many 
physiological and pathological processes (i.e. development, aging, wound healing, 
hypertension, cancer). Changes in the protein profile of normal human dermal fibroblasts 
were investigated in vitro after 96h in 5% CO2 and 21% O2 (pO2=140mmHg) or 2% O2
(pO2=14mmHg), these parameters representing a mild chronic hypoxic exposure which 
fibroblasts may undergo in vivo. The proliferation rate and the protein content were not 
significantly modified by hypoxia, whereas  proteome analysis demonstrated changes in the 
expression of 56 proteins. Protein identification was performed by mass spectrometry.  Data 
demonstrate that human fibroblasts respond to mild hypoxia increasing the expression of 
hypoxia inducible factor (HIF1a) and of the 150 kDa oxygen regulated protein. Other 
differentially expressed proteins appeared to be related to stress response, transcriptional 
control, metabolism, cytoskeleton, matrix remodelling and angiogenesis. Furthermore, some 
of them, like galectin 1, 40S ribosomal protein SA, N-myc-downstream regulated gene-1 
protein, that have been described in the literature as possible cancer markers, significantly 
changed their expression also in normal hypoxic fibroblasts. Interestingly, a bovine fetuin was 
also identified that appeared significantly less internalised by hypoxic fibroblasts. In 
conclusion, results indicate that human dermal fibroblasts respond to an in vitro mild chronic 
hypoxic exposure by modifying a number of  multifunctional proteins. Furthermore, data 
highlight the importance of stromal cells in modulating the intercellular cross-talk occurring 
in physiological and in pathologic conditions.
31. Introduction
Fibroblasts are important stromal cells that synthesize the structural components of the 
extracellular matrix, but they also migrate within the stroma in order to interact with other 
cells and with the extracellular milieu according to different stimuli [1-3]. However, in 
physiological as well as in pathologic conditions, fibroblasts may be frequently found distant 
from blood vessels, where they are forced to adapt to mild hypoxia. 
Hypoxia in fibroblasts is known to induce an upregulation of growth factors such as 
transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), insulin 
growth factor (IGF-1) and to favour extracellular matrix remodelling mainly through 
modulation of metalloproteases, activation of lysyl oxidase [4], stimulation of collagen type I 
synthesis [5,6] and reduced expression of elastin [7,8]. 
In addition, there are several other circumstances, as during wound healing, where capillary 
injury generates a hypoxic environment in which fibroblasts, and subsequently 
myofibroblasts, are attracted in order to activate the repair processes [9]. Experimental 
findings support the theory that fibroblasts play a significant role in the vascular response to 
injury, being capable to proliferate, transdifferentiate and migrate under hypoxic conditions 
through hypoxia inducible factor (HIF) activation [10,11].
Interestingly, there are evidence suggesting that HIF is functionally connected to senescence 
[12], and that aging is associated to high incidence of ischemic diseases where connective 
tissue homeostasis is severely compromised.
Moreover, during cancer progression, many tumors develop a hypoxic microenvironment in 
which oxygen delivery to neoplastic as well as to stromal cells is frequently reduced or even 
abolished. Tumor cells can survive and even grow in such a deteriorated microenvironment 
and their aggressiveness as well as their capacity to invade surrounding tissues are dependent 
4on the stroma produced by fibroblasts, suggesting that these cells may tightly interact and/or 
influence cancer cell behaviour [2,13,14].
Although a large number of studies have focused on the influence of hypoxia on the 
expression and the posttranslational modifications of a single protein or of a subset of 
functionally related proteins, only some of them have examined proteome-wide alterations 
during hypoxia [15-20] and few data are available for human fibroblasts [21,22].
Given the importance of fibroblasts in connective tissue homeostasis and their interactions 
with other cells in normal and pathological conditions [23-24], aim of the present study was to 
investigate changes in the protein profile of in vitro normal human dermal fibroblasts in 
primary cell culture exposed to mild chronic hypoxia [25].
2. Materials and Methods
2.1 Cells and treatments
Human dermal fibroblasts were taken from the upper thigh during surgery after informed 
consent from 3 clinically healthy females (45 ± 7 years), which did not exhibit any sign of 
genetic, metabolic or connective tissue disorders. The adopted procedure was in accordance 
with the guidelines of the ethical committee of the Modena University Faculty of Medicine. 
Fibroblasts were used between 5th and 7th passages and routinely cultured in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM 
glutamine, 100 IU/ml penicillin, and 100 ug/ml streptomycin. Cells from each subject were 
kept separate during all experiments.
Hypoxic conditions were established by culturing fibroblasts in two different incubators as 
previously described [26]. In control experiments an incubator (KW Apparecchi Scientifici, 
Siena, Italy) set at 5% CO2, 20% O2 (atmospheric oxygen  140 mmHg) in a humidified 
environment at 37°C was used. Experiments under hypoxic conditions were performed using 
5a water-jacketed incubator (Forma Scientific, Marietta, OH, USA) providing a customized 
and stable humidified environment through electronic control of CO2 (5%), O2 and 
temperature (37°C). The O2 tension was set and constantly maintained at 2% ( 14 mmHg) by 
automatically injecting N2 in the chamber. 
All experiments under hypoxia exposure were performed after 24 hours from seeding on 
synchronized cells (overnight in DMEM + 0.2% FBS). During experiments fibroblasts were
cultured in DMEM + 10% FBS.
2.2 Cell proliferation 
Proliferation was assessed using the CyQuant cell proliferation assay (Molecular Probes, OR, 
USA). In this assay, the CyQuant dye binds to DNA, and the emitted fluorescence is linearly 
proportional to the number of cells in the well. Fibroblasts were seeded at a density of 4000 
cells/well in a 96-well black fluorescence micro-titre plates and allowed to attach for 4-8 h in 
DMEM + 10% FBS. After overnight starving (0,2% FBS), medium was replaced with 10% 
FBS and plates were simultaneously incubated for 48, 72 and 96 hours at 37°C in normoxic or 
hypoxic condition. At appropriate times, the medium was discarded, plates were washed with 
phosphate buffered saline (PBS) and frozen at -80°C until use. On the day of the analysis, 
plates with adherent cells were thawed and incubated with a buffer containing the CyQuant
dye. Fluorescence was measured using a Fluostar optima (BMG LABTEACH Offenburg-
Germany) multi-well plate reader with excitation 485 nm and emission 520 nm [27]. Three 
separate experiments were performed independently.
2.3  HIF quantitation
Equal amounts of proteins, determined using a kit from Pierce (Rockford, IL), were resolved 
on 10% SDS/polyacrylamide gels, and transferred to a nitrocellulose membrane 
6(Schleicher&Schuell, Keene, NH). Membranes were blocked with 5% non-fat dry milk in 
Tris-buffered saline containing 0.1% Tween-20 (TBST) at room temperature for 1 hour and 
then incubated overnight at 4°C with a primary antibody for HIF-1 (BD Biosciences, San 
Jose, CA) diluted 1:250 and for -actin (housekeeping gene, Cell Signaling Technology, 
Beverly, MA) diluted 1:2000, in 5% non-fat dry milk in TBST. Membranes were then 
incubated with a horseradish peroxidase-conjugated secondary antibody (diluted 1:5000 in 
5% non-fat dry milk in TBST) for 1 hour and the antigen-antibody complexes were visualized 
using an Immuno-star HRP kit (Bio-Rad Laboratories, Hercules, CA ). Immunoreactive bands 
were digitalized with a charge-coupled device camera gel documentation system 
(ChemiDocXRS, Bio-Rad), and quantified with the Quantity One software (Bio-Rad). -actin 
was used in the same gel to normalize the amounts of total protein present in the samples.
2.4   Proteome analysis
2.4.1. Sample preparation
Synchronized fibroblasts were grown for 96h in DMEM plus 10% FBS in normoxia and 
hypoxia. Afterwards, cells were detached from flasks by incubation in 0.25% Trypsin in PBS 
for 10 min at 37°C. After washes in DMEM plus FBS and proteinase inhibitors (1mM 
ethylenediaminetetraacetic acid (EDTA), 10M  -aminocaproic acid, 50mM benzamidine) 
cells were centrifuged at 1000g for 10 min. After supernatant removal, pellets were 
resuspended in PBS plus proteinase inhibitors, centrifuged at 1000g for 10min, and 
immediately resuspended in lysis buffer (8M urea, 2% 3-[(3-
cholamidopropyl)dimethylamonio]-1-propanesulfonate (CHAPS), 65mM dithioerythritol, 2% 
pharmalyte pH 3–10 and trace amount of bromophenol blue). Protein concentration was 
determined according to Bradford [28]. Cells from each subject were kept separate during all 
experiments. 
72.4.2. Two-dimensional gel electrophoresis (2D-GE)
2D-GE was performed, essentially as described by Bjellqvist et al. [29], in two independent 
assays where the three different cell lines exposed to normoxia and hypoxia were run in 
duplicate.
Samples containing 60 µg (analytical gels) or 1 mg (preparative gels) of protein underwent 
2D-GE using the Immobiline/polyacrylamide system [29]. Isoelectric focusing was performed 
on IPGphor system (GE- Healthcare, Uppsala, Sweden) at 16°C using two different protocols. 
For analytical gels: passive rehydratation for 16h, 500 V for 1h, 500-2000V for 1h, 3500V for 
3h, 5000V for 30 min and 8000 V for 12h.  For preparative gels a preliminary step at 200V 
constant for 12h was added. Thereafter, immobilized pH gradient strips were reduced (2% 
dithioerythritol) and alkylated (2.5% iodoacetamide) in equilibration buffer (6M urea, 50mM 
Tris-HCl, pH 6.8, 30% glycerol, 2% SDS). When the equilibration phase was finished, strips 
were loaded onto 12% acrylamide vertical gels using an Ettan DALTsix electrophoresis unit 
(GE- Healthcare, Uppsala, Sweden). 
Analytical gels were stained with ammoniacal silver nitrate [30]; preparative gels for mass 
spectrometric analysis were silver-stained as described by Shevchenko et al. [31].
2.4.3. Data acquisition and analysis
To detect significant differences in protein abundance between the two experimental 
conditions, all silver-stained gel images were digitalized at 400 dpi resolution using 
ImageScanner (GE- Healthcare) and analyzed using Melanie 3.0 software (GE- Healthcare, 
Uppsala, Sweden). After background subtraction, protein spots were automatically defined 
and quantified with the feature detection algorithm [30]. Spot intensities were expressed as 
percentages (% vol) of relative volumes by integrating the optical density (OD) of each pixel 
in the spot area (vol) and dividing with the sum of volumes of all spots detected in the gel.
8Only those spots that, within the same experimental condition, exhibited the same trend of 
expression in all gels underwent  further quantitative analysis.
Quantitative data were exported as a text file to be elaborated using Microsoft Excel program. 
Mean values, standard deviations and coefficients of variation were calculated using the 
Excel-provided formulas.
Statistical data were obtained using GraphPad software (San Diego, CA, USA) and data were 
compared by the unpaired t-test; differences between treatments were considered significant 
at p< 0.05.
Only those spots whose expression appeared significantly changed by hypoxia were selected 
for MS analysis. 
2.4.4. In-gel destaining and digestion of protein samples
Spots of interest were manually excised from preparative silver- stained 2-DE gels. Silver-
stained gel pieces were destained as described by Gharahdaghi et al. [33]. Briefly, gel spots
were incubated in 100 mM sodium thiosulfate and 30 mM potassium ferricyanide, rinsed 
twice in 25 mM ammonium bicarbonate (AmBic) and once in water, shrunk with 100% 
acetonitrile (ACN) for 15 min, and dried in a Savant SpeedVac for 20–30 min. All excised 
spots were incubated with 12.5 ng/µl sequencing grade trypsin (Roche Molecular 
Biochemicals, Basel, CH) in 25 mM AmBic overnight at 37°C. Peptide extraction was carried 
out twice using first 50% ACN, 1% trifluoroacetic acid (TFA) and then 100% ACN. All 
extracts were pooled, and the volume was reduced by SpeedVac.
2.5 Mass Spectrometry
2.5.1. MALDI-TOF MS
The tryptic peptide extracts were redissolved in 12µl 0.1% TFA. The matrix (-cyano-4-
hydroxycinnamic acid, HCCA) was purchased from Laser BioLabs (Sophia-Antipolis, 
France). A saturated solution of HCCA (1µl) at 2mg/200µl in CH3CN/H2O (50/50 v/v) 
9containing 0.1% TFA was mixed with 1µl of peptide solution on the MALDI target and left to 
dry.
MALDI-TOF mass spectra were recorded on a Voyager DE-PRO (Applied-Biosystems, 
Courtaboeuf, France) mass spectometer, in the 700-5000 Da mass range using a minimum of 
200 shots of laser per spectrum. Delayed extraction source and reflector equipment allowed 
sufficient resolution to consider MH+ of monoisotopic peptide masses. Internal calibration 
was done using trypsin autolysis fragments at m/z 842.5100, 1045.5642 and 2211.1046 Da. 
PMF was compared to the theoretical masses from the Swiss-Prot 49.1 or the NCBI (march 
2006 database release) databases using MS-Fit 3.1.1 from ProteinProspector 3.2.1 
(http://www.expasy.org/tools/). Typical search parameters were as follows:  30ppm of mass 
tolerance; carbamidomethylation of cysteine residues; one missed enzymatic cleavage for 
trypsin; a minimum of four peptide mass hits was required for a match (when the matched 
peptide number was low, the delta mass difference between experimental measured masses 
and exact masses from the data base was evaluated and it was checked if masses of peptides 
were in the same range); methionine residues could be considered in oxidized form; no 
restriction was placed on the pI and molecular weight of the protein. The minimum 
signal/noise ratio was generally between 5/1 to 10/1, depending on the spectrum quality. 
Finally, triptic digests that did not produced unambiguous protein identification were 
successively subjected to HPLC/MS.
2.5.2. HPLC/MS
Peptides were resuspended in aqueous 5% formic acid and subsequently eluted onto a 150mm 
x 75µm Atlantis C18 column analytical (Waters, Milford, MA, USA) and separated with an 
increasing ACN gradient from 10% to 85% in 30 min. using a Waters CapLC system. The 
analytical column (extimated flow approx. 200nanoL/min) was directly coupled, through a 
nanoES ion source, to a Q-TOF Ultima Global mass spectrometer (Waters, Milford, MA, 
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USA). Multicharged ions (charge states 2, 3 and 4) were selected for fragmentation and the 
acquired MS/MS spectra were searched against the SWISS-PROT/TrEMBL non-redundant 
protein and NCBI database using the Mascot (www.matrixscience.com) MS/MS search 
engine.
Initial search parameters were the follows: enzyme, trypsin; maximum number of missed 
cleavages, 1; fixed modification, carbamidomethylation of cysteines; variable modification 
parameters, oxidation Met; peptide tolerance, 0.5 Da; MS/MS tolerance, 0.3 Da; charge state, 
2, 3, or 4.
We basically selected the candidate peptides with probability-based MOWSE scores that 
exceeded its threshold, indicating a significant (or extensive) homology (p<0.05), and referred 
to them as “hits”. The criteria were based on the manufacturer’s definitions (Matrix Science, 
Boston, MA, USA) [32]. Proteins that were identified with at least two peptides both showing 
a score higher than 40, were validated without any manual processing. Those with at least two 
peptides whose score was lower than 40 and higher than 20 were systematically checked 
and/or interpreted manually to confirm or cancel the MASCOT suggestions. For protein 
identified by only one peptide, its score has to exceed 30, and its peptide sequence was 
systematically checked manually. 
2.6 Immunoblot
Protein extracts were processed, electrophoresed (30µg proteins/lane) on 10-lane 1-DE 
10% polyacrylamide gel under reducing conditions and transferred to a nitrocellulose 
membrane. The membrane was blocked in TBST + 5% non fat dry milk for 1 h at room 
temperature. The primary antibodies, all purchased from Abcam (Cambridge, UK), were 
diluted in TBST + 2,5% non fat dry milk as follows: a) filamin 1:1000 (goat polyclonal, 
ab11074); b) protein disulfide isomerase 1:1000 (mouse monoclonal, ab2792); c) heat shock 
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protein60 1:10000 (Mouse monoclonal, ab13532); d) enolase-1 1:30000 (rabbit polyclonal, 
ab49343); e) heat shock protein-27 1:1000 (mouse monoclonal, ab2790); f) calmodulin 1:500 
(mouse monoclonal, ab2860); g) galectin 1 1:5000 (rabbit polyclonal, ab25138); h) 
thioredoxin 1:2000 (rabbit polyclonal, ab16835). The membrane were incubated with primary 
antibodies at room temperature for 60 min. The following secondary antibodies were used 
after washing three times in TBST: horseradish peroxidase (HRP)-conjugated sheep anti-
mouse immunoglobulin antibody 1:5000 (GE Healthcare) or donkey anti-goat IgG 1:15000 
(ab6885, Abcam, Cambridge, UK) or donkey anti-rabbit IgG 1:20000 (ab6802, Abcam, 
Cambridge, UK). Subsequently, membranes were washed three times in TBST and Western 
blots were visualized using the ECL plus detection system (GE Healthcare) as described in 
the technical manual provided by the company. Images were analysed using ImageQuant TL 
v2005 software in order to automatically determine the band volumes.
3. Results 
3.1  Cell proliferation
In our experimental conditions, hypoxia did not significantly modified the proliferation of 
dermal fibroblasts, as evaluated by the CyQuant cell proliferation assay after 48, 72 and 96h 
of treatment (data not shown).
Moreover, cells in the two experimental conditions were similar as far as their morphology.
3.2  HIF determination
HIF accumulation was evaluated by Western blot, using antibodies recognizing HIF1and 
HIF2(figure 1a). Densitometric evaluation of HIF bands normalised to -actin was 
performed in all cell lines and confirmed a significant (p<0.05) increase of HIF-1after 96 
12
hours of hypoxia (figure 1b), whereas HIF2 did not changed in the two experimental 
conditions (data not shown).
3.3 Protein profile evaluation
By 2D-GE approximately 2500 proteins were separated from each cell line, independently 
from the experimental conditions.
The experimental intra-samples variability was measured by analysing changes in the volume 
of 600 protein spots on duplicate 2D gels from the same sample. Spot location and intensities 
were very similar between gels from the same sample. The coefficient of variation (CV% 
calculated by the standard deviation of the normalized spot volumes divided by the mean of 
values, expressed as a percent) was also analysed in order to quantify intra-sample (20%) and 
inter-samples (32%) variability. Values were similar to those already described in the 
literature [35].
The hypoxic condition determined statistically significant changes (p<0.05) in the expression 
of 56 proteins, indicated by the arrows on two representative gels obtained from normoxic 
and hypoxic fibroblasts (figure 2). In particular, 32 proteins appeared significantly 
upregulated under hypoxia, whereas 24 proteins were significantly downregulated (figure 3). 
By mass spectrometry we have identified about 63% of the differentially expressed proteins 
in the whole cell lysate (table 1). The remaining proteins were either in insufficient amount to 
be analyzed by MS or MS/MS or the MS-compatible staining procedure failed to reveal them.
Only in the case of spot 16, MS revealed the presence of two different proteins in the same 
spot: namely actin 1/2 and protein disulfide-isomerase.
It has to be mentioned that, for some proteins, we identified spots that did not match with the 
predicted Mr or pI, indicating once more the presence of different isoforms and/or fragments 
as already shown by other Authors [36]. 
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Surprisingly, all identified proteins were produced by human fibroblasts, with the exception 
of fetuin, that was of bovine origin. Even though cells were placed in the same culture 
medium, hypoxic fibroblasts showed, i.e. retained, a significantly reduced amount of bovine 
fetuin within the cell monolayer.
Each identified protein was assigned to a functional classification based on the Gene 
Ontology annotation system using the DAVID database bioinformatic resources 
(http://david.abcc.ncifcrf.gov) (table 2).  GO is a structured, controlled vocabulary that 
describes gene products in terms of their associated biological processes, cellular components 
and molecular functions. The protein distribution into functional categories is reported in 
figure 4. It can be noted that proteins were grouped into 15 different categories, some proteins 
belonging to more than one category due to their multifunctional properties. 
3.4   Immunoblot verification of protein changes 
To validate results of  proteome analysis, immunoblot experiments were performed  on 1D 
SDS-PAGE using specific antibodies for filamin,  protein disulfide isomerase, heat shock 
protein-27, heat shock protein-60, enolase-1, calmodulin, galectin 1 and thioredoxin (figure 
5). Data were generally in agreement with those observed at proteome level; however in  the 
case of filamin C, where two isoforms, by proteome analysis (spot 1 and 2), exhibited  
different protein changes, one being upregulated, wheres the other was downregulated, 
immunoblot revealed that filamin C was globally downregulated  upon hypoxia. 
Furthermore, in the case of spot 16, that MS demonstrated to be actually formed by two 
proteins (i.e. actin 1/2 and protein disulfide isomerase), immunoblot data revealed a marked 
upregulation of  protein disulfide isomerase in hypoxic conditions. Therefore, the global 
downregulation of spot 16 could be attributable to a downregulation of the actin isoform,
14
consistently with the reduced expression also of the other actin isoform corresponding to spot 
11. 
4. Discussion
Albeit hypoxia is a stress condition that in some circumstances can compromise cell viability 
leading to growth arrest and apoptosis [37], human fibroblasts, similarly to other cell lines
[18] are highly resistant to the hypoxic condition, being even capable to heighten proliferation 
capabilities [38,39]. In the experimental conditions described in this study, differences 
between normoxic and hypoxic fibroblasts were negligible as far as their growth capabilities 
and cell morphology, indicating that fibroblasts in the presence of chronic mild hypoxia 
exposure can well adapt themselves.  
In the present investigation, cells were grown for 96 hour at 140 (normoxia) or 14 mmHg
(hypoxia) pO2. These parameters have been selected because oxygen pressure in tissues 
decreases with increasing distance from blood vessels reaching values of  pO2  as low as 0.5 –
2.5 kPa (4–20 mm Hg) [25], and therefore a mild (2%) chronic (up to four days) hypoxia can 
be considered a condition that stromal cells may frequently experience, depending  on local  
physiological and pathological stimuli.
Furthermore, a four day exposure allows cell to stabilize their phenotype in the new 
environment, and changes should not be regarded as a transient response, but the result of a 
real adaptation to hypoxia. 
4.1. Oxygen responsive proteins
Human dermal fibroblasts responded to mild chronic hypoxia exposure by increasing the 
expression of HIF1whereas HIF 2as expected did not exhibited any significant 
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change. Therefore, changes in fibroblast protein profile are the consequence of low oxygen 
availability.
In addition to HIF1 accumulation, hypoxia determined a significant up-regulation of the 150 
kDa oxygen regulated protein (ORP150), an inducible chaperone that facilitates the protein 
transport/processing in the endoplasmic reticulum under low oxygen tension [42]. It is 
expressed in a range of pathologic situations such as ischemic brain, atherosclerotic plaques 
and malignant tumours, suggesting that it may contribute to cellular response to 
environmental stress. Moreover, in low ambient oxygen concentrations, ORP150, is likely to 
subserve a cytoprotective role at the level of the endoplasmic reticulum, enhancing cellular
ability to sustain oxygen deprivation [43], as indicated by the ability of fibroblasts to adapt to 
hypoxia. Consistently with its up-regulation upon hypoxia, it has been demonstrated that 
OPR150 promotes angiogenesis favouring the transport and secretion of VEGF [42], a 
cytokine which plays a fundamental role in wound healing and in cancer progression. This 
finding further supports the role of hypoxia in modulating fibroblast behaviour and tissue 
remodelling.
4.2. Stress responsive proteins
Hypoxia can be considered a stress condition capable to modulate cell phenotype through 
activation of several stress-response pathways [44]. In our experimental conditions, we have 
shown an up-regulation of Hsp27, which is probably mediated through HIF-1 activation [45]. 
Hsp27 has been demonstrated to act as an anti-apototic protein with a cytoprotective effect
[46], consistently with the high resistance of fibroblasts to various stress conditions (personal 
observation).
By contrast, upon mild chronic hypoxia exposure, Hsp60 appeared significantly reduced both 
by proteome analysis and by immunoblot. Hsp60 is a mitochondrial protein that is important 
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for folding key proteins after import into the mitochondria. It has been demonstrated that, 
during hypoxia, Hsp60 cellular distribution changes, with Hsp60 leaving the cytosol and 
translocating to the plasma membrane [47]. Since it is well known that analysis of membrane 
proteins may offer some difficulties when two-dimensional gel electrophoresis conventional 
protocols are used, it cannot be excluded that reduced expression of Hsp60 is simply the 
consequence of cellular redistribution of the protein to the plasma membrane, or, possibly, the 
consequence of functional differences between various stress proteins [44].
In addition to Hsp(s), also some oxidative stress-related proteins, namely peroxiredoxin and 
thioredoxin, appeared to be significantly less expressed by hypoxic fibroblasts. In particular, 
peroxiredoxin belongs to a family of multifunctional antioxidant thioredoxin-dependent 
peroxidases, thus exerting a cellular protection against oxidative stress, modulating 
intracellular signalling cascades and regulating cell proliferation [48]. The observation that 
peroxiredoxin is homologous to the natural killer enhancing factor, allowed to hypothesize 
that hypoxic fibroblasts have a lower capability to protect cells from oxidative damage, or to 
selectively promote NK citotoxicity against certain tumor cells [49]. Furthermore, recent 
evidence highlighted the role of peroxiredoxin as important  tumor suppressors [48], playing a 
role in preventing the oxidative damage which may activate pathways leading to aggressive 
tumors [50].
Similarly to peroxiredoxin, also thioredoxin was significantly less expressed in human 
fibroblasts upon hypoxia. Thioredoxin is an ubiquitous oxidoreductase with strong cytokine, 
chemoattractant and anti-apoptotic activities [51]. These data seem to support the hypothesis 
that hypoxia may modulate the cellular cross-talk within stromal connective tissue, and that, 
regarding oxidative stress, hypoxia may prevent the production of free radicals, thus down-
regulating the expression of anti-oxidant molecules.
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4.3. Proteins related to cell metabolism
There are several papers indicating that one of the major metabolic consequences of the 
hypoxic condition is the activation of glycolitic enzymes such as aldolase A and C, enolase, 
lactate dehydrogenase, phosphofructokinase L, phoshoglycerate kinase, pyruvate kinase and 
glyceraldehyde-3-phosphate dehydrogenase, possibly through HIF-mediated transcription 
induction [52]. In our experimental conditions, some of these enzymes were only moderately 
increased under mild hypoxia, without reaching a statistical significance. In particular, four 
glyceraldehyde-3-phosphate dehydrogenase isoforms were identified increasing their 
expression from 10% to 15% in hypoxic condition, the phosphoglycerate kinase raises of 20% 
and fructose aldolase increases 2,5 fold. These findings indicate that in hypoxic fibroblasts 
several glycolytic enzymes are only moderately  affected.
In the case of triosephosphate isomerase (TPI), this protein was significantly increased upon 
hypoxia, as already demonstrated by other Authors at both mRNA and protein levels [53], 
suggesting that this upregulation, by increasing the flow of triosephosphate through the 
glucolytic cascade, may lead to anaerobic energy generation. Unlike the previously described 
enzymes, it could be suggested that TPI is a glycolytic enzyme particularly sensitive to 
hypoxia.
As far as enolase, a statistically significant up-regulation of two isoforms has been shown
(p<0.05). Enolase catalyzes the formation of phosphoenolpyruvate from 2-phosphoglycerate, 
but evidence indicates that it may function, other than a glycolytic enzyme, as a modulator of 
growth control as well as of thermal and hypoxia tolerance. Moreover, enolase may act as a 
cell surface receptor for plasminogen, suggesting that fibroblasts in a hypoxic environment 
favour proteolytic activities on the cell surface [54], thus contributing to matrix remodelling.
Interestingly, we have shown that hypoxic fibroblasts upregulate the expression of  
parathymosin, a  zinc-binding protein, which is known to interacts with several enzymes 
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involved in carbohydrate metabolism and to inhibit the binding of the activated glucocorticoid
receptor to nuclei. More recently, parathymosin has been demonstrated to act modulating H1 
interactions with chromatin and affecting the condensation state of chromatin fibers allowing 
to hypothesize that parathymosin may participate in global chromatin remodeling during gene 
activation and perhaps during the transcription initiation process itself [55-57]. Therefore, it is 
conceivable to suggest that increased expression of parathymosin may influence the protein 
profile, as a consequence of  chromatin structure remodelling.
4.4. Cytoskeletal related proteins 
A large network of physically interconnected cellular components, starting from the structural 
components of the cell nucleus, via cytoskeleton filaments to adhesion molecules and the 
extracellular matrix, constitutes an integrated matrix that functions as a scaffold allowing the 
cell to cope with changes of the microenvironment. Several cytoskeletal and cytoskeletal-
related molecules are significantly affected by hypoxia, most of these proteins appeared to be 
upregulated, i.e. tubulins, transgelin and lamins. Lamins, for instance, are intranuclear class of 
intermediate filament proteins being part of the nuclear envelope and playing a role in nuclear 
integrity maintenance, in chromatin organization and in transcriptional control modulation 
[58]. The upregulation of different lamin isoforms may contribute to hypoxia-related changes 
in the protein profile through increased nuclear strength and activation of transcription factors
[59].
More intriguing is the different response of  two filamin C isoforms, as revealed by proteome 
analysis. Interestingly, validation of protein changes by immunoblot, demonstrated that 
filamin C was globally down-regulated upon hypoxia. Filamin-C belongs to the filamin 
family of actin binding proteins. Beside its role in crosslinking actin filaments into a 3D 
structure, filamin has been reported to directly interact with more than 30 cellular proteins, 
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among which membrane receptors for cell signalling molecules [60]; nevertheless, the 
physiological significance of most of these interactions is still unknown. Given the 
multifunctional role of filamins [61], the occurrence of isoform switching as well as of 
alternative mRNA splicing and of different post-translational modifications, namely 
phosphorylation [62], it could be assumed that filamin C isoforms: i) may exert  various 
biological role by interacting with various molecules, ii) may have a different susceptibility to 
hypoxia, iii) may interact with some, but not all actin filaments, indicating that hypoxia  can 
be responsible for filamin redistribution and actin rearrangement, as observed in other stress
conditions [63].
4.5. Tumour-related proteins
The microenvironment of solid tumours present hypoxic regions and several hypoxia-
regulated genes may contribute to tumour progression and treatment resistance [64]. Within 
this context,  stromal cells, being regulated by reduced oxygen tension,  may actively 
contribute to  modulate the transformed phenotype [24].
Mild chronic hypoxia, for instance, caused a down-regulation of the N-myc downstream 
regulated gene1 protein (NDRG1), that shuttles between cytoplasm and nucleus upon several 
insults [65]. This protein has been shown to be markedly up-regulated in several tumour cell 
lines. Surprisingly, our data indicate that NDRG1 is expressed also by normal fibroblasts, 
although its expression, differently from tumour cells, is decreased upon hypoxia. These data 
may indicate that oxygen-responsive proteins can be differentially regulated depending on 
cell type and that stromal cells may interfere with the overall evaluation of this protein as a 
potential cancer marker.
Galectin 1 is involved in numerous biological functions, i.e. cell-cell and cell-substrate 
interactions and induction of apoptosis of activated T-lymphocytes,  and is over-expressed in 
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tumours and/or in the tissue surrounding neoplastic proliferation [66]. Previous data already 
demonstrated that galectin 1 is expressed by endothelial cells from capillaries infiltrating 
tumours such as prostate carcinoma [67] and it has been hypothesized that galectin 1 
expression in the endothelium close to tumours could provide cancer cells with increased 
abilities to interact with endothelial cells as well as a defence against the host immune system. 
Data from the present study, by proteome analysis as well as by immunoblot, indicate that 
galectin 1 is over-expressed in hypoxic fibroblasts, and therefore it could be suggested that in 
hypoxic conditions, as in cancer progression, stromal cells may contribute, as endothelial cells 
[67] and cancer cells [68], to the aggressiveness of tumours.
Several factors are known to contribute to severity and aggressiveness of tumour cells and 
hypoxia has been shown to reduce the efficacy of conventional radiotherapy and to diminish 
survival prognosis [69]. 
In our experimental model, hypoxia up-regulated the expression of the 40S ribosomal protein 
SA also known as a multidrug resistance associated protein MGr1-Ag or as a human 34-67 
kDa laminin receptor, thus highlighting the involvement of mesenchymal cells, such as 
fibroblasts, in the stromal tissue response to hypoxia.
The strong relationship between hypoxia, stroma and cancer development is further supported 
by the up-regulation of elongation factor 1 (EF1α), an ubiquitous cellular protein, 
responsible for the GTP-dependent recruitment of aminoacyil-tRNAs to the ribosome during 
the elongation cycle of protein translation [70], even though, several other non-canonical 
functions have been ascribed to EF-1α, including microtubule severing, actin filament 
bounding, oncogenic transformation and ubiquitin-dependent proteolysis of N-terminus 
proteins [71-73]. 
Furthermore, it has to be mentioned that  hypoxia-induced matrix remodelling may be further 
supported by the increased expression of annexin I and II. Annexin I inhibits the expression 
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and/or the activity of inflammatory enzymes such as the inducible nitric oxide synthase and 
cyclooxigenase and contribute to the anti-inflammatory signalling allowing safe-post-
apoptotic clearance of dead cells [74]. Moreover, it has been demonstrated that annexin II
serves as a profibrinolytic coreceptor for both plasminogen and tissue plasminogen activator, 
and it has been shown that the abundant presence of annexin II on the cell surface [75] may 
contribute to the invasive potential through the extracellular matrix [76], to the activation of 
other metalloproteases and/or to the release of matrix-bound angiogenic growth factors. There 
is in fact evidence that some proteases and proteases receptor expression are under the control 
of tumour hypoxia, which is the result of an imbalance in oxygen supply and demand [77]. 
Present data underline, once more, that hypoxia modulates fibroblast protein profile and that 
stromal cells are active and crucial players in several pathologic processes [78].
4.6. Serum-derived proteins
All identified proteins were produced by human fibroblasts, with the exception of fetuin, that 
was of bovine origin. Even though cells were placed in the same culture medium, hypoxic 
fibroblasts seemed to retain a significant reduced amount of bovine fetuin within the cell 
monolayer, suggesting that fibroblasts, in vitro, can incorporate the fetuin present in the 
culture media as already observed in human vascular smooth muscle cells [79].
Fetuin is a protein synthesized by the liver and abundantly present in serum, and in several 
tissues and organs where acts as an important inhibitor of ectopic calcification [80]. 
Present data indicate that hypoxic fibroblasts have a reduced serum fetuin uptake. It could be 
speculated that, in vivo, hypoxic cells could internalise a significantly lower amount of fetuin 
from the extracellular compartment, thus perturbing calcium homeostasis, as observed during 
atherosclerosis, chronic renal failure and cancer, leading to ectopic calcifications.
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4.7.  Concluding remarks
The maintenance of oxygen homeostasis is crucial during embryonic development and in 
postnatal life [81] and a better comprehension of the pathways involved in the response to 
changes in oxygen availability might have important biological and therapeutic implications 
[82]. Cells can respond to changes in oxygen availability with a rapid feedback mediated 
through post-translational modifications or membrane depolarisation [83] and with a “late 
hypoxic response pathway” affecting gene and protein expression over several hours. These 
last changes are mediated, at least in part, through the induction of hypoxia-inducible 
transcription factors as HIF [84], which is considered a marker of the ability of the cells to 
respond to the hypoxic condition. Even though several genes, that are modulated by HIF, 
have been described in numerous cell lines undergoing hypoxia [85], a large-scale analysis of 
changes occurring in the protein profile of hypoxic normal human fibroblasts is still absent.
Fibroblasts, one of the most abundant cells of connective tissues, are responsible for protein 
synthesis and turnover and produce factors possibly modulating other cell types [86-89].
A better comprehension of the pathways affected in human fibroblasts upon mild chronic 
hypoxia exposure may get further light on the intercellular cross-talk and on tissue 
remodelling occurring in physiological and in pathological conditions [2,3]. 
Data indicate that mild chronic hypoxia modulates fibroblast protein profile by inducing 
significant changes in the expression of 56 proteins. The 35 identified proteins fell into 15
different functional categories, according to the GO annotation system, indicating that 
hypoxia might interfere with a broad range of functional activities such as transcriptional 
control, angiogenesis, matrix remodelling,  stress response and energy metabolism.
In conclusion, although further studies are necessary in order to deeper examine each 
potentially activated pathway, this study clearly indicates that human dermal fibroblasts 
respond to a mild chronic hypoxic condition by modifying several proteins that might 
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influence the intercellular cross-talk occurring in several physiologic and pathologic 
conditions, as during embryogenesis, aging, wound healing and tumor progression.
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LEGEND TO FIGURES
Figure 1. HIF quantitation. Representative Western blot (a) showing the expression of HIF-
1α, HIF-2 and -actin in human dermal fibroblasts grown in normoxia (N) and hypoxia 
(H).Hypoxia significantly increased the protein accumulation of HIF-1α, but not HIF-2. 
Data in panel b are mean values ± SD of densitometric evaluations of HIF-1 normalized to 
-actin in Western blots made with three different cell lines. Three different experiments were 
performed. * p<0,05 Hypoxia vs Normoxia
Figure 2. 2DGE. Representative silver-stained 2-D electropherograms of the cell layer of
human dermal fibroblasts cultured in normoxia (left) and hypoxia (right). Arrows and 
numbers denote the position of differentially expressed proteins.
Figure 3. Differentially expressed proteins. Changes in protein expression are represented in 
the chart according to the value of the expression factor (R) according to the equation  R=log2 
(H/N). H is the % mean volume of the spot in hypoxia and N is the % mean volume of the 
spot in normoxia. Proteins that did not changed their expression have R=0. Proteins are 
identified by numbers, as in figure 2.
Figure 4. Functional classification. Distribution of all human identified protein isoforms, 
according to the Gene Ontology (GO) annotation system, was performed using the DAVID 
database bioinformatic resources (http://david.abcc.ncifcrf.gov). The percentage of 
upregulated/downregulated proteins in hypoxia is reported for each function category.
Figure 5. Western blots.  Immunoblots were performed in order to validate changes in the 
expression of filamin (FLN), protein disulfide isomerase (PDI), heat shock protein 60 
33
(HSP60), heat shock protein 27 (HSP27), enolase 1 (ENO1),  calmodulin (CALM), galectin 1 
(LEG1), thioredoxin (TRX) in normoxia (N) and hypoxia (H).  A quantitative representation 
of changes are visualized by histograms adjacent to immunoblots.
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3 final revision
Figure 4
Figure 5
1TABLE 1
List of identified proteins whose expression significantly (p<0.05 Normoxia vs Hypoxia)
changed upon hypoxia
# a) Name and acc. no. b)
pI/
MW c)
Identification method d)
1 Filamin C Q14315
5.4/
200
MS/MS – 161; 6; 3%
2 Filamin C Q14315
5.2/
200
PMF - 7.44e+011; 26/32; 11%
3 Fetuin-A P12763
3.8/
90
MS/MS – 225; 4; 19%
4 150 kDa oxygen-regulated protein Q9Y4L1
4.8/
105
MS/MS –68; 3; 5%
5 HSP 60 P10809
5.4/
65
PMF - 6.58e+004; 10/18; 24%
7 Lamin A/C P02545
6.7/
56
PMF - 5.07e+004; 12/14; 20%
8 Elongation factor 1-alpha 1 P68104
9.0/
50 MS/MS – 192; 5; 22%
9 NDRG1 protein Q92597
5.4/
45
MS/MS – 38; 1, 3%
11
Actin 1 P60709/
Actin 2 P63261
6.4/
42
PMF - 1.91e+004; 7/8; 22%
   16a
+ 16b
Actin1/2 P60709/P63261
+
Protein disulfide-isomerase P07237
4.8/
41
PMF - 1.59e+08; 14/ 36; 53%
+
PMF - 3.37e+003; 9/36; 19%
17 Alpha enolase P06733
6.4/
40
PMF - 1.13e+007; 9/11; 28%
19 Tubulin alpha-3 chain Q71U36
5.0/
40
MS/MS –505; 8; 27%
21 Tubulin beta-2 chain P07437
4.7/
38
MS/MS – 610; 10; 35%
23 Tropomyosin 1 alpha chain P09493
4.7/
37
PMF - 3.95e+006; 11/25; 40%
25 40S ribosomal protein SA P08865
4.0/
36
MS/MS – 113; 2; 12%
26 Alpha enolase P06733
5.6/
36
MS/MS – 651; 14; 48%
27 Annexin A2 P07355
7.0/
35
PMF - 1.51e+010; 17/24; 58%
28 Protein disulfide isomerase A3 P30101
5.4/
30
MS/MS – 189; 4; 11%
30
Actin 1 P60709/
actin 2 P63261
5.0/
28
PMF - 7.2e+004; 6/20; 20%
31 Heat shock cognate 71kDa protein P11142
6.8/
28
PMF - 2.93e+006; 13/18; 26%
32 Triosephosphate isomerase P60174
7.2/
26
PMF - 4.13e+007; 13/18;65%
33 Annexin A1 P04083
4.8/
26
PMF - 7.63e+009; 15/22; 57%
35 HSP 27 P04792
6.4/
24
PMF - 5.25e+004; 8/10; 43%
36 Pyruvate kinase M1/M2 isozyme 66910342
5.9/
22
MS/MS – 171; 4; 24%
Table 1
237 Peroxiredoxin 2 P32119
5.3/
22
PMF - 1.07e+005; 9/18; 44%
39 HSP 90-beta P08238
6.0/
20
MS/MS – 130; 4; 7%
41
Lamin A protein 386856 5.3/
19
MS/MS – 84; 2; 6%
42 Parathymosin P20962
3.7/
18
MS/MS – 71; 1; 15%
43 T-complex protein 1 subunit beta P78371
5.1/
17
MS/MS – 120; 4; 12%
44 Tubulin beta 2 chain 38511503
3.8/
16
MS/MS – 210; 5; 56% 
45 Calmodulin 1 P62158
3.6/
16
MS/MS – 115; 3; 43%
46 Transgelin Q01995 
8.8/
15
PMF - 3.96e+004; 7/13; 41%
49
Prolyl 4-hydroxylase alpha-1 subunit precursor
190786
6.3/
16
MS/MS – 243; 5; 7%
50 Pyruvate kinase M1/M2 isozyme Q8WUW7
7.2/
15
MS/MS – 204; 4; 14%
51 Galectin 1 P09382
5.1/
14
PMF - 6.15e+0.003; 5/11; 43%
53 Thioredoxin P10599
4.7/
11
MS/MS – 97; 3; 32%
Detailed protein identification data are available from Table 1 supplementary material
a) Protein number as reported on gels in figure 2
b) Protein name and accession number according to Swiss_Prot/TrEMBL and NCBI databases
c) Experimental pI and Mr (kDa)
d) For MS/MS sequencing the following parameters are given: total score (i.e. the sum of scores
of all peptides), number of matched peptides; % coverage
For PMF the following parameters are given: Mowse score; number of matched peptides/ total 
peptides; % coverage
TABLE 2
Distribution of identified human proteins into functional categories according to the GO annotation 
system (http://david.abcc.ncifcrf.gov).
Category Function
Proteins and protein 
isoforms a)
Macromolecule 
metabolism
The chemical reactions and pathways involving 
macromolecules, large molecules including proteins, nucleic 
acids and carbohydrates.
4, 5, 8, 16b, 17, 19, 21, 25, 
26, 31, 32, 35, 36, 42, 44, 
49, 50
Regulation of biological 
process
Any process that modulates the frequency, rate or extent of a 
biological process. Biological processes are regulated by many 
means; examples include the control of gene expression, 
protein modification or interaction with a protein or substrate 
molecule.
5, 8, 17, 21, 23, 25, 26, 33, 
35, 37, 42, 44, 51
Localization
The processes by which a cell, a substance or a cellule entity, 
such as a protein complex or organelle, is transported to, 
and/or maintained in a specific location.
5, 11, 16a, 16b, 19, 21, 23, 
28, 30, 33, 35, 44, 53
Generation of precursor 
metabolites and energy
The chemical reactions and pathways resulting in the 
formation of precursor metabolites, substances from which 
energy is derived and the processes involved in the liberation 
of energy from these substances.
4, 16b, 17, 26, 28, 32, 36, 
50, 53
Cellular biosynthesis
The chemical reactions and pathways resulting in the 
formation of substances carried out by individual cells.
8, 17, 25, 26, 32, 35, 36, 
50
Response to stress
A change in the state or activity of a cell or an organism (in 
terms of movement, secretion, enzyme production, gene 
expression, etc.) as a result of a stimulus indicating the 
organism is under stress. The stress is usually, but not 
necessarily, exogenous (e.g. temperature, humidity, ionizing 
radiation).
4, 5, 31, 33, 35, 37, 42
Cell death
The specific activation or halting of processes within a cell so 
that its vital functions markedly ceases, rather than simply 
deteriorating gradually over time, which culminates in cell 
death.
5, 21, 33, 35, 37, 44, 51
Catabolism
The chemical reactions and pathways resulting in the 
breakdown of substances, including the breakdown of carbon 
compounds with the liberation of energy for use by the cell or 
organism.
4, 17, 26, 32, 36, 50
Protein folding
The process of assisting in the covalent and noncovalent 
assembly of single chain polypeptides or multisubunit 
complexes into the correct tertiary structure.
4, 5, 31, 35, 39, 43
Response to chemical 
and/or abiotic stimulus
A change in state or activity of a cell or an organism (in terms 
of movement, secretion, enzyme production, gene expression, 
etc) as a result of a chemical and/or abiotic stimulus.
5, 9, 31, 35, 37
Intracellular transport The directed movement of substances within a cell. 5, 19, 21, 28, 44
Development
A biological process whose specific outcome is the progression 
of an integrated living unit: a cell, tissue, organ, or organism 
over time from an initial condition to a later condition.
7, 27, 41, 46
Response to unfolded 
proteins
A change in state or activity of a cell or an organism (in terms 
of movement, secretion, enzyme production, gene expression, 
etc.) as a result of an unfolded protein stimulus.
5, 31, 35
Protein polymerization
The process creating protein polymers, compounds composed 
of a large number of component monomers; polymeric proteins 
may be made up of different or identical monomers. 
Polymerization occurs by the addition of extra monomers to an 
existing poly-or oligomeric protein.
19, 21, 44
Translation
A ribosome-mediated process in which the information in 
messenger RNA (mRNA) is used to specify the sequence of 
amino acids in a polypeptide chain.
8, 25, 35
Not classified 1, 2, 45
a ) proteins present in each  functional category are indicated  by the corresponding number on gels. 
Table 2
TABLE 1S 
List of identified proteins whose expression significantly changed (p<0.05) upon hypoxia
# a)
Name  and 
acc. no. b)
pI/
MW c)
Identification method
For MS/MS sequencing: % coverage, peptide sequence, ion score, charge state
For PMF: Mowse score; % coverage and peptide sequence matched are given
M* - Methionine oxidation
1
Filamin C
Q14315
5.4/
200
MS/MS – 3%
R.AFGPGLEGGLVNK (ion score 33) (+2)
R.APLQVAVLGPTGVAEPVEVR (ion score 22) (+2) 
R.EVTTEFTVDAR (ion score 22) (+2) 
R.GAGGQGQLDVR (ion score 34) (+2)
R.SLTATGGNHVTAR (ion score 20) (+2) 
R.SPFEVQVSPEAGVQK (ion score 30) (+2) 
2
Filamin C
Q14315
5.2/
200
PMF - 7.44e+011; 11% 
(K) LKPGAPVR(S) 
(K) VVPNNDKDR(T) 
(K) VTVLFAGQNIER(S) 
(R) DTVEVALEDKGDSTFR(C) 
(K) GTEEPVKVR(E) 
(R) SPFEVQVSPEAGVQK(V) 
(R) VNVGEGSHPER(V) 
(K) YTPPGAGR(Y) 
(K) VAVGQEQAFSVNTR(G) 
(R) GAGGQGQLDVR(M) 
(R) MTSPSRRPIPCK(L) 
(K) ATIRPVFDPSK(V) 
(R) ASGPGLER(G) 
(K) VSGPGVEPHGVLR(E) 
(R) EVTTEFTVDAR(S) 
(R) SLTATGGNHVTAR(V)
(K) TDTYVTDNGDGTYR(V) 
(R) FTVETR(G) 
(R) APLQVAVLGPTGVAEPVEVR(D)
(K) YADQEVPR(S) 
(R) ASGPGLNASGIPASLPVEFTIDAR(D)
(K) YGGDEIPYSPFR(I) 
(R) IQIGQETVITVDAK(A)
(K) YVITIR(F) 
(R) FDDKHIPGSPFTAK(I) 
(K) ITESDLSQLTASIR(A) 
3
Fetuin-A
P12763
3.8/
90
MS/MS -19%
K.HTLNQIDSVK.V (ions score 58) (+2)
K.CDSSPDSAEDVR.K (ions score 82) (+2)
R.HTFSGVASVESSSGEAFHVGK.T (ions score 21) (+3)
K.TPIVGQPSIPGGPVR.L (ions score 64) (+2)
4
150 kDa oxygen-
regulated protein
Q9Y4L1
4.8/
105
MS/MS – 5%
K.LGNTISSLFGGGTTPDAK.E (ions score 29) (+2)
K.AEAGPEGVAPAPEGEKK.Q (ions score 20) (+3)
K.AANSLEAFIFETQDK.L (ions score 19) (+2)
5
HSP 60
P10809
5.4/
65
PMF - 6.58e+004; 24%
(K) LVQDVANNTNEEAGDGTTTATVLAR(S)
(K) GANPVEIRR(G) 
(K) ISSIQSIVPALEIANAHR(K) 
(R) KPLVIIAEDVDGEALSTLVLNR(L) 
(K) APGFGDNRK(N) 
(K) AQIEKR(I) 
(R) IQEIIEQLDVTTSEYEKEK(L)
(R) VTDALNATR(A) 
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(R) AAVEEGIVLGGGCALLR(C)  
(K) IGIEIIKR(T) 
7
Lamin A/C 
P02545
6.7/
56
PMF - 5.07e+004; 20%
(R) SGAQASSTPLSPTR(I) 
(R) LQEKEDLQELNDR(L) 
(R) LAVYIDR(V) 
(R) SLETENAGLR(L) 
(K) EAALSTALSEKR(T) 
(R) TLEGELHDLR(G) 
(K) NIYSEELRETK(R)
(R) LADALQELR(A)
(R) NSNLVGAAHEELQQSR(I)
(R) IRIDSLSAQLSQLQK(Q)
(K) LRDLEDSLAR(E) 
(K) LALDMEIHAYR(K) 
8
Elongation factor 
1-alpha 1
P68104
9.0/
50
MS/MS – 22%
K.YYVTIIDAPGHR.D (ions score 65) (+2)
R.LPLQDVYK.I (ions score 29) (+2)
K.IGGIGTVPVGR.V (ions score 44) (+2)
K.SGDAAIVDMVPGKPMCVESFSDYPPLGR.F (ions score 28) (+3)
R.QTVAVGVIK.A (ions score 26) (+2)
9
NDRG1 protein 
Q92597
5.4/
45
MS/MS – 3%
R.TASGSSVTSLDGTR.S (ions score 38) (+2)
11
Actin 1/
Actin 2
P60709/
P63261
6.4/
42
PMF - 1.91e+004; 22%
(K) AGFAGDDAPR(A) 
(R) AVFPSIVGRPR(H) 
(R) VAPEEHPVLLTEAPLNPK(A)
(R) GYSFTTTAER(E)
(K) SYELPDGQVITIGNER(F) 
(K) IIAPPER(K)
(K) QEYDESGPSIVHR(K) 
16a
+ 
16b
Actin1/2
+
Protein disulfide-
isomerase
P60709/
P63261
+
P07237
4.8/
41
PMF - 1.59e+08; 53%
(-) DDDIAALVVDNGSGMCK(A)
(K) AGFAGDDAPR(A) 
(R) AVFPSIVGRPR(H) 
(K) RGILTLK(Y) 
(R) VAPEEHPVLLTEAPLNPK(A) 
(R) TTGIVM*DSGDGVTHTVPIYEGYALPHAILR(L)
(R) LDLAGRDLTDYLMK(I)
(R) GYSFTTTAEREIVR(D)
(R) DLTDYLMK(I)
(K) LCYVALDFEQEMATAASSSSLEK(S) 
(K) SYELPDGQVITIGNER(F) 
(K) CDVDIRK(D)
(K) DLYANTVLSGGTTMYPGIADR(M)
(K) IIAPPERK(Y) 
+
PMF - 3.37e+003; 19%
(K) LKAEGSEIR(L) 
(K) VDATEESDLAQQYGVR(G) 
(K) YQLDKDGVVLFK(K)
(K) KFDEGR(N) 
(K) HNQLPLVIEFTEQTAPK(I)
(K) IFGGEIK(T) 
(K) ILFIFIDSDHTDNQR(I)
(K) KEECPAVR(L)
(R) ITEFCHR(F) 
17
Alpha enolase 
P06733
6.4/
40
PMF - 1.13e+007; 28%
(R) EIFDSR(G) 
(R) GNPTVEVDLFTSK(G)
(R) AAVPSGASTGIYEALELR(D) 
(K) FGANAILGVSLAVCK(A)
(K) DATNVGDEGGFAPNILENK(E)
(K) VVIGMDVAASEFFR(S)
(R) YISPDQLADLYK(S) 
(K) FTASAGIQVVGDDLTVTNPK(R)
(R) IEEELGSK(A) 
19
Tubulin alpha-3 
chain
Q71U36
5.0/
40
MS/MS – 27%
K.TIGGGDDSFNTFFSETGAGK.H (ions score 96) (+2)
R.AVFVDLEPTVIDEVR.T (ions score 85) (+2)
R.QLFHPEQLITGKEDAANNYAR.G (ions score 68) (+3)
K.EIIDLVLDR.I (ions score 45) (+2)
R.LSVDYGK.K (ions score 20) (+2)
R.NLDIERPTYTNLNR.L (ions score 36) (+2)
R.LIGQIVSSITASLR.F (ions score 64) (+2)
R.IHFPLATYAPVISAEK.A (ions score 91) (+2)
21
Tubulin beta-2 
chain
P07437
4.7/
38
MS/MS – 35%
-.M*REIVHIQAGQCGNQIGAK.F (ions score 26) (+3)
R.ISVYYNEATGGK.Y (ions score 76) (+2)
R.AILVDLEPGTMDSVR.S (ions score 51) (+2)
R.SGPFGQIFRPDNFVFGQSGAGNNWAK.G (ions score 62) (+3)
K.GHYTEGAELVDSVLDVVR.K (ions score 77) (+3)
R.IM*NTFSVVPSPK.V (ions score 86) (+2)
R.FPGQLNADLR.K (ions score 66) (+2)
K.LAVNM*VPFPR.L (ions score 43) (+2)
R.LHFFMPGFAPLTSR.G (ions score 65) (+3)
R.ALTVPELTQQVFDAK.N (ions score 58) (+2)
23
Tropomyosin 1 
alpha chain 
P09493
4.7/
37
PMF - 3.95e+006; 40%
(K) QLEDELVSLQK(K)
(K) ATDAEADVASLNR(R) 
(R) IQLVEEELDR(A) 
(R) IQLVEEELDRAQER(L) 
(R) LATALQKLEEAEK(A)
(K) LEEAEKAADESER(G)
(R) AQKDEEKMEIQEIQLK(E)
(K) HIAEDADR(K) 
(K) YEEVARK(L)
(K) LVIIESDLER(A)
(R) AEFAER(S) 
25
40S ribosomal 
protein SA
P08865
4.0/
36
MS/MS – 12%
R.AIVAIENPADVSVISSR.N (ions score 56) (+2)
K.FAAATGATPIAGR.F (ions score 57) (+2)
26
Alpha enolase 
P06733
5.6/
36
MS/MS – 48%
R.AAVPSGASTGIYEALELR.D (ions score 36) (+3)
K.TIAPALVSKK.L (ions score 36) (+2)
K.LMIEMDGTENK.S (ions score 58) (+2)
K.FGANAILGVSLAVCK.A (ions score 41) (+2)
K.GVPLYR.H (ions score 23) (+2)
R.HIADLAGNSEVILPVPAFNVINGGSHAGNK.L (ions score 62) (+4)
K.LAMQEFMILPVGAANFR.E (ions score 36) (+2)
R.IGAEVYHNLK.N (ions score 49) (+2)
K.DATNVGDEGGFAPNILENK.E (ions score 63) (+2)
K.EGLELLK.T (ions score 40) (+2)
K.VVIGMDVAASEFFR.S (ions score 61) (+2)
R.SGKYDLDFK.S (ions score 39) (+2)
R.YISPDQLADLYK.S (ions score 53) (+2)
K.FTASAGIQVVGDDLTVTNPK.R (ions score 54) (+2)
27
Annexin A2 
P07355
7.0/
35
PMF - 1.51e+010; 58%
(-)STVHEILCK(L) 
(K) AYTNFDAER(D) 
(K) TKGVDEVTIVNILTNR(S) 
(R) QDIAFAYQR(R)
(K) SALSGHLETVILGLLK(T) 
(K) TPAQYDASELK(A)
(K) GLGTDEDSLIEIICSR(T) 
(R) TNQELQEINR(V) 
(K) TDLEKDIISDTSGDFR(K)
(K) LMVALAK(G) 
(R) AEDGSVIDYELIDQDAR(D)
(R) DLYDAGVK(R)
(K)WISIMTER(S) 
(K) VFDRYK(S) 
(K) SYSPYDMLESIR(K)
(R) LYDSMK(G)
(R) DKVLIR(I) 
28
Protein disulfide 
isomerase A3 
P30101
5.4/
30
MS/MS – 11%
R.LAPEYEAAATR.L (ions score 69) (+2)
K.YGVSGYPTLK.I (ions score 45) (+2)
R.DGEEAGAYDGPR.T (ions score 52) (+2)
R.TADGIVSHLKK.Q (ions score 23) (+3)
30
Actin 1/
actin 2 
P60709/
P63261
5.0/
28
PMF - 7.2e+004; 20%
(R) GYSFTTTAER(E) 
(K) SYELPDGQVITIGNER(F) 
(K) CDVDIRK(D) 
(K) DLYANTVLSGGTTMYPGIADR(M)
(K) IIAPPER(K) 
(K) QEYDESGPSIVHR(K)
31
Heat shock 
cognate 71kDa 
protein 
P11142
6.8/
28
PMF - 2.93e+006; 26%
(K) GPAVGIDLGTTYSCVGVFQHGK(V)
(K) VEIIANDQGNR(T) 
(R) TTPSYVAFTDTER(L) 
(K) NQVAMNPTNTVFDAK(R)
(K) VQVEYKGETK(S) 
(K) MKEIAEAYLGK(T) 
(K) TVTNAVVTVPAYFNDSQR(Q) 
(K) DAGTIAGLNVLR(I) 
(R) IINEPTAAAIAYGLDKK(V) 
(K) STAGDTHLGGEDFDNR(M) 
(R) MVNHFIAEFK(R) 
(K) DISENKR(A) 
(R) GTLDPVEKALR(D) 
32
Triosephosphate 
isomerase
P60174
7.2/
26
PMF - 4.13e+007; 65%
(K) VPADTEVVCAPPTAYIDFAR(Q)
(R) QKLDPK(I) 
(K) IAVAAQNCYK(V) 
(K) DCGATWVVLGHSER(R) 
(R) RHVFGESDELIGQK(V) 
(K) VAHALAEGLGVIACIGEK(L)
(K) LDEREAGITEK(V) 
(K) VVFEQTK(V)
(K) VIADNVKDWSK(V)
(K) VVLAYEPVWAIGTGK(T)
(K) TATPQQAQEVHEK(L)
(K) SNVSDAVAQSTR(I)
(R) IIYGGSVTGATCK(E) 
33
Annexin A1 
P04083
4.8/
26
PMF - 7.63e+009; 57%
(-)AMVSEFLK(Q) 
(K) QAWFIENEEQEYVQTVK(S) 
(K) GGPGSAVSPYPTFNPSSDVAALHK(A)
(K) GVDEATIIDILTK(R) 
(K) RNNAQR(Q) 
(K) AAYLQETGKPLDETLKK(A) 
(K) ALTGHLEEVVLALLK(T) 
(K) TPAQFDADELR(A) 
(K) GLGTDEDTLIEILASR(T) 
(R) TNKEIR(D)
(R) DLAKDITSDTSGDFR(N)
(R) SEDFGVNEDLADSDAR(A) 
(R) ALYEAGER(R) 
(K) GTDVNVFNTILTTR(S) 
(R) SYPQLR(R)
35
HSP 27
P04792
6.4/
24
PMF - 5.25e+004; 43%
(R) VPFSLLR(G) 
(R) LFDQAFGLPR(L) 
(R) QLSSGVSEIR(H) 
(R) HTADRWR(V) 
(R) VSLDVNHFAPDELTVK(T) 
(K) DGVVEITGKHEER(Q)
(R) QDEHGYISR(C)
(K) LATQSNEITIPVTFESR(A)
36
Pyruvate kinase 
M1/M2 isozyme
66910342
5.9/
22
MS/MS – 24%
R.TATESFASDPILYRPVAVALDTK.G (ions score 27) (+3)
K.ITLDNAYMEK.C (ions score 20) (+2)
K.IYVDDGLISLQVK.Q (ions score 82) (+2)
K.GADFLVTEVENGGSLGSK.K (ions score 42) (+2)
37
Peroxiredoxin 2 
P32119
5.3/
22
PMF - 1.07e+005; 44%
(R) IGKPAPDFK(A) 
(K) ATAVVDGAFKEVK(L)
(R) AEDFRK(L) 
(K) EGGLGPLNIPLLADVTR(R) 
(R) LSEDYGVLK(T)
(K) TDEGIAYR(G) 
(R) GLFIIDGK(G) 
(R) QITVNDLPVGR(S) 
(R) SVDEALR(L) 
39
HSP 90-beta
P08238
6.0/
20
MS/MS – 7%
K SIYYITGESK (ions score 36) (+3)
K EQVANSAFVER (ions score 30) (+2)
K.LGIHEDSTNR (ions score 34) (+2)
R YHTSQSGDEMTSLSEYVSR (ions score 30) (+3)
41
Lamin A protein
386856
5.3/
19
MS/MS – 6%
R.TALINSTGEEVAM*R.K (Ions score 26) (+2)
R.SVGGSGGGSFGDNLVTR.S (Ions score 58) (+2)
42
Parathymosin
P20962
3.7/
18
MS/MS – 15%
-.SEKSVEAAAELSAK.D (ions score 71) (+2)
43
T-complex 
protein 1 subunit 
beta
P78371
5.1/
17
MS/MS – 12%
R DASLMVTNDGATILK (ions score 28) (+2)
R EALLSSAVDHGSDEVK (ions score 41) (+2)
R QDLMNIAGTTLSSK (ions score 21) (+2)
R VQDDEVGDGTTSVTVLAAELLR (ions score 30) (+3)
44
Tubulin beta 2 
chain 
38511503
3.8/
16
MS/MS – 56% 
K.EVDEQMLNVQNK.N (ions score 20) (+2)
K.NSSYFVEWIPNNVK.T (ions score 31) (+2)
K.TAVCDIPPR.G (ions score 44) (+2)
K.MAVTFIGNSTAIQELFKR.I (ions score 58) (+3)
R.ISEQFTAMFR.R (ions score 57) (+2)
45
Calmodulin 1 
P62158
3.6/
16
MS/MS – 43%
K.DGNGFISAAEL.R (score ione 35) (+2)
K.EAFSLFDKDGDGTITT.K (score ione 40) (+2)
K.DTDSEEEI.R (score ione 40) (+2)
46
Transgelin 
Q01995 
8.8/
15
PMF - 3.96e+004; 41%
(K) YDEELEER(L) 
(R) LVEWIIVQCGPDVGRPDR(G) 
(K) QMEQVAQFLK(A) 
(K) TDMFQTVDLFEGKDMAAVQR(T)
(K) NDGHYR(G) 
(K) AQEHKR(E)
(R) GASQAGMTGYGRPR(Q)
49
Prolyl 4-
hydroxylase 
alpha-1 subunit 
precursor
190786
6.3/
16
MS/MS – 7%
R.LQDTYNLDTDTISKGNLP.G (ions score 80) (+2)
K.SFLTAEDCFELGK.V (ions score 31) (+2)
K.LLELDPEHQR.A (ions score 49) (+3)
K.GVAVDYLPER.Q (ions score 49) (+2)
R.QKYEMLCR.G (ions score 34) (+2)
50
Pyruvate kinase 
M1/M2 isozyme
Q8WUW7
7.2/
15
MS/MS – 14%
K.GDYPLEAVR.M (ions score 46) (+2)
R.MQHLIAR.E (ions score 25) (+2)
R.LAPITSDPTEATAVGAVEASFK.C (ions score 68) (+2)
K.CCSGAIIVLTK.S (ions score 65) (+2)
51
Galectin 1
 P09382
5.1/
14
PMF - 6.15e+0.003; 43%
(-)ACGLVASNLNLKPGECLR(V)
(R) VRGEVAPDAK(S) 
(K) DSNNLCLHFNPR(F) 
(K) DGGAWGTEQR(E)
(K) LPDGYEFK(F) 
53
Thioredoxin 
P10599
4.7/
11
MS/MS – 32%
TAFQEALDAAGDK (ions score 41) (+2)
EKLEATINELV (ions score 30) (+2)
VGEFSGANK (ions score 26) (+2)
a) Protein number as reported on gels in figure 2
b) Protein name and accession number according to Swiss_Prot/TrEMBL and NCBI databases
c) Experimental pI and Mr (kDa)
